C P Cannon

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:1395-402. 1999
  2. ncbi request reprint Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 99:751-6. 1999
  3. ncbi request reprint Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 283:2941-7. 2000
  4. ncbi request reprint Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
    C P Cannon
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:149-56. 2000
  5. ncbi request reprint Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 134:622-30. 1997
  6. ncbi request reprint Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 344:1879-87. 2001
  7. ncbi request reprint Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy
    E M Antman
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:326-30. 1998
  8. ncbi request reprint Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
    C P Cannon
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    J Am Coll Cardiol 24:1602-10. 1994
  9. ncbi request reprint Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 141:742-50. 2001
  10. ncbi request reprint Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    J Am Coll Cardiol 25:582-9. 1995

Detail Information

Publications34

  1. ncbi request reprint Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:1395-402. 1999
    ..We sought to review the emerging data and the clinical rationale for combining glycoprotein (GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AMI)...
  2. ncbi request reprint Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 99:751-6. 1999
    ....
  3. ncbi request reprint Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 283:2941-7. 2000
    ..Rapid time to treatment with thrombolytic therapy is associated with lower mortality in patients with acute myocardial infarction (MI). However, data on time to primary angioplasty and its relationship to mortality are inconclusive...
  4. ncbi request reprint Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
    C P Cannon
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 102:149-56. 2000
    ..Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events...
  5. ncbi request reprint Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 134:622-30. 1997
    ..The availability of a reliable, noninvasive serum marker of reperfusion may permit early identification of patients with occlusion after thrombolysis who might benefit from further interventions...
  6. ncbi request reprint Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 344:1879-87. 2001
    ..There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation...
  7. ncbi request reprint Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy
    E M Antman
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:326-30. 1998
    ..We sought to determine whether the rapid bedside assay for troponin T identified patients at risk for a more complicated hospital stay and a higher rate of adverse clinical events...
  8. ncbi request reprint Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
    C P Cannon
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    J Am Coll Cardiol 24:1602-10. 1994
    ..The aim of our study was to determine a superior thrombolytic regimen from three: anistreplase (APSAC), front-loaded recombinant tissue-type plasminogen activator (rt-PA) or combination thrombolytic therapy...
  9. ncbi request reprint Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
    R P Giugliano
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 141:742-50. 2001
    ..The optimal heparin dose as an adjunct to fibrinolysis and its role in causing intracranial hemorrhage (ICH) is unclear...
  10. ncbi request reprint Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    J Am Coll Cardiol 25:582-9. 1995
    ..This study attempted to determine which lesion characteristics are associated with reocclusion by 18 to 36 h...
  11. ncbi request reprint Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 35:358-62. 2000
    ....
  12. ncbi request reprint C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction
    D A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 31:1460-5. 1998
    ....
  13. ncbi request reprint The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia
    C P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 30:133-40. 1997
    ..We sought to determine the prognostic value of the admission electrocardiogram (ECG) in patients with unstable angina and non-Q wave myocardial infarction (MI)...
  14. ncbi request reprint Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial
    C M Gibson
    Department of Medicine, The Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 80:21-6. 1997
    ....
  15. doi request reprint Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial
    Michelle L O'Donoghue
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 123:1843-53. 2011
    ..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...
  16. ncbi request reprint Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy
    D A Morrow
    Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1812-7. 2000
    ....
  17. ncbi request reprint Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 87:636-9, A10. 2001
    ..2% vs 3.2% to 3.6% for WBC count < 10,000; p < 0.000). With its simplicity and widespread availability, WBC count could serve as a simple, inexpensive, new tool for risk stratification in acute coronary syndromes...
  18. ncbi request reprint The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes
    J A de Lemos
    Thrombolysis in Myocardial Infarction Study Group, Boston, USA
    N Engl J Med 345:1014-21. 2001
    ....
  19. ncbi request reprint Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3
    D A Morrow
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:1356-9. 2001
    ..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population...
  20. ncbi request reprint Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B
    M J Tanasijevic
    Clinical Laboratories, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 34:739-47. 1999
    ....
  21. ncbi request reprint Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy
    C M Gibson
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Circulation 103:2550-4. 2001
    ..These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI...
  22. ncbi request reprint Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect
    M J Sagarin
    Harvard Affiliated Emergency Medicine Residency Program, Harvard Medical School, Boston, Massachusetts, USA
    J Emerg Med 16:557-65. 1998
    ..The inclusion of patients in this separate population in a general analysis of median door-to-drug times results in an artificial asymptote effect and may confound quality initiatives...
  23. ncbi request reprint Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial
    D A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 286:2405-12. 2001
    ....
  24. doi request reprint Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 123:1854-63. 2011
    ..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD...
  25. ncbi request reprint "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry
    N K Sekaran
    Harvard Medical School, and Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thromb Thrombolysis 12:207-16. 2001
    ....
  26. doi request reprint Combination therapy in the management of mixed dyslipidaemia
    C P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Intern Med 263:353-65. 2008
    ..Careful monitoring is required when adding additional agents given the increased potential for drug interactions and side effects...
  27. ncbi request reprint Myocardial infarction: contemporary management strategies
    E V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Intern Med 262:59-77. 2007
    ..Finally, evidence-based approach to secondary prevention is outlined...
  28. ncbi request reprint The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists
    D C Shields
    Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
    Pharmacogenomics J 2:182-90. 2002
    ..004). Thus, genetic polymorphisms may be associated with subsequent myocardial infarction, and may also be associated with treatment-associated bleeding among coronary patients...
  29. ncbi request reprint Enoxaparin in ST elevation MI - a bright future
    C P Cannon
    Eur Heart J 23:591-2. 2002
  30. ncbi request reprint Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes
    F F O'Connor
    Department of Clinical Pharmacology, and Surgen Ltd, Royal College of Surgeons in Ireland
    Blood 98:3256-60. 2001
    ..In patients presenting with an acute coronary syndrome, the Pl(A) polymorphism of GPIIb/IIIa may explain some of the variance in the response to an oral GPIIb/IIIa antagonist...
  31. ncbi request reprint New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction
    J S Hochman
    Division of Cardiology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284, USA
    Arch Intern Med 161:674-82. 2001
    ....
  32. ncbi request reprint Ischemic preconditioning: implications for the geriatric heart
    R A Kloner
    Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Am J Geriatr Cardiol 10:145-8; quiz 149-51. 2001
    ..This observation may lead to a clinical counterpart to successful preconditioning in the older heart...
  33. ncbi request reprint Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy
    V S Srinivas
    Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
    Am Heart J 142:29-36. 2001
    ..A low 12-hour myoglobin level (< or = 239 ng/mL in this substudy) identifies such patients at low risk and could potentially assist in early risk stratification and triage after ST-segment elevation myocardial infarction...
  34. ncbi request reprint The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction
    P F Bray
    Department of Medicine, Thrombosis Research Section, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 88:347-52. 2001
    ..These data suggest that it would be important to perform a larger study to address the potential role of these genotypes in therapeutic decision making...